Elotuzumab (Empliciti, Bristol-Myers Squibb) is an anti-SLAMF7 monoclonal antibody indicated in the treatment of multiple myeloma. The drug is administered as an IV infusion. This section discusses the common adverse reactions, warnings and precautions, drug interactions and other contraindications associated with elotuzumab therapy.
Common adverse reactions
Warnings and precautions
Drug interactions and other contraindications
Elotuzumab common adverse reactions
Adverse reactions occurring in at least 20% of clinical trials participants receiving elotuzumab included fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite and pneumonia.
Elotuzumab warnings and precautions
Dexamethasone, antihistamines and acetaminophen must be administered before infusion because of the risk for infusion reactions. Elotuzumab should be interrupted in the event of a severe infusion reaction.
Infections, including opportunistic fungal and viral infections, have been reported. Patients should be closely monitored for signs of infection and should receive prompt and appropriate treatment.
An increased rate of second primary malignancies was noted in clinical trials in patients receiving elotuzumab in combination with lenalidomide (Revlimid, Celgene). Patients should be closely monitored for signs of second primary malignancy.
Elotuzumab drug interactions and other contraindications
No known drug interactions or other contraindications are associated with elotuzumab therapy.